 The switch of entacapone to OPC led to significantly greater reductions in OFF-time.
Results

Introduction
Levodopa still remains the most effective symptomatic treatment for Parkinson's disease (PD). However, following oral administration, levodopa is extensively metabolized in the periphery by dopa decarboxylase and catechol-O-methyltransferase (COMT). Opicapone (OPC) is a novel 3 rd generation COMT inhibitor developed to fulfil the need for a more potent, safer and longer acting COMT inhibitor [1, 2] . OPC has shown to be safe and effective in reducing OFF-time in two pivotal studies in patients with PD and motor fluctuations (BIPARK I and II) [3, 4] . Patients completing these studies could enroll into an open-label (OL) extension with OPC for 1-year. Here we report the efficacy and safety results of the extension phase of BIPARK I study.
Treatment-Emergent and Serious Adverse Events (TEAEs and SAEs)
 A total of 337 (68.1%) subjects reported at least one TEAE.  Most TEAEs were of mild or moderate intensity; the incidence of severe TEAEs was 9.7%.  Thirty-three (6.7%) subjects prematurely discontinued due to AEs.  The incidence of SAEs was low (10.3%). There were no SAEs related to hepatic toxicity.  Eleven (2.2%) deaths were reported, none of which were considered drug related. Potentially related: drug-event relationship reported as "possible", "probable", "definite" by the Investigator or missing * 2 subjects who withdrew consent due to the TEAE Parkinson's disease 
Objective
To evaluate the efficacy and safety profile of OPC as add-on to levodopa over 1 year of treatment in patients with PD and motor fluctuations. 
Efficacy and safety of opicapone in patients with Parkinson's disease and motor fluctuations: 1-year follow-up (BIPARK I)
Efficacy
 At OL Endpoint, the mean OFF-time was further decreased by -33.8 min relative to the OL Start, i.e. an improvement of more than 2 hours (-126.9 min) relative to DB Baseline.  For subjects who received placebo or entacapone in the DB period, the switch to OPC resulted in a significant decrease of OFF-time .9] and -39.3 min [95% CI: -67.6, -11.1], respectively) ( Table 3 ).  The means for OFF-time at OL Endpoint were comparable irrespective of prior DB treatment (Figure 3 ).  The mean levodopa dose at OL endpoint was 637.6 mg/day, below the OL Start level. Multiple reasons for discontinuation could be specified for a given subject.
* Includes 3 subjects who withdrew consent due to an adverse event
